Prediction of in vitro metabolic stability of calcitriol analogs by QSAR
- 146 Downloads
The metabolic stability of a drug is an important property for potential drug candidates. Measuring this property, however, can be costly and time-consuming. The use of quantitative structure-activity relationships (QSAR) to estimate the in vitro stability is an attractive alternative to experimental measurements. A data set of 130 calcitriol analogs with known values of in vitro metabolic stability was used to develop QSAR models. The analogs were encoded with molecular structure descriptors computed mainly with the commercial software QikProp and DiverseSolutions. Variable selection was carried out by five different variable selection techniques and Partial Least Squares Regression (PLS) models were generated from the 130 analogs. The models were used for prediction of the metabolic stability of 244 virtual calcitriol analogs. Twenty of the 244 analogs were selected and the in vitro metabolic stability was determined experimentally. The PLS models were able to predict the correct metabolic stability for 17 of the 20 selected analogs, corresponding to a prediction performance of 85%. The results clearly demonstrate the utility of QSAR models in predicting the in vitro metabolic stability of calcitriol analogs.
Unable to display preview. Download preview PDF.
- 6.Reichrath, J. and Holick, M.F., In Holick, M.F. (Ed.), Vitamin D: Physiology, Molecular Biology, and Clinical Applications, Vol. 1. Humana Press Inc., Totowa, NJ,1999, pp. 357–374.Google Scholar
- 7.Holick, M.F. In Holick, M.F. (Ed.), Vitamin D: Physiology, Molecular Biology, and Clinical Applications, Vol. 1. Humana Press Inc., Totowa, NJ, 1999, pp. 207–216.Google Scholar
- 8.Holick, M.F. In Holick, M.F. (Ed.), Vitamin D: Physiology, Molecular Biology, and Clinical Applications, Vol. 1. Humana Press Inc., Totowa, NJ,1999, pp. 1–16.Google Scholar
- 15.Wold, S., Martens, H. and Wold, H., In Kågström, B. and Ruhe, A., (Eds.), Lecture Notes in Mathematics Vol.973. Springer-Verlag, Berlin,1983, pp. 286–293.Google Scholar
- 17.Kissmeyer, A.-M., Mathiasen, I.S., Latini, S. and Binderup, L., Endocrine, 3 (1995)263.Google Scholar
- 18.Kissmeyer, A.-M., Preclinical pharmacokinetics and metabolism of EB1089 and other vitamin D analogs, Leo Pharmaceutical Products Ltd, Denmark,2000.Google Scholar
- 20.Pearlman, R.S. and Smith, K.M., Perspect. Drug Discov. Des., 9/10/11 (1998)339.Google Scholar
- 30.Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R. and Clementi, S., Quant. Struct.-Act. Rel.,12 (1993) 9.Google Scholar
- 31.Holland J.H. (Ed.) Adaption in Natural and Artificial Systems. University of Michigan Press, Am Arbor, Michigan,1975.Google Scholar
- 33.Wold, S., Technometrics,20 (1978)397.Google Scholar
- 35.Calverly, M.J., Binderup, E. and Binderup, L. In Norman, A.W., Bouillon, R. and Thomasset, M., (Eds.), Proceedings on the Eighth Workshop on Vitamin D, Paris, France, 5–10 July 1991, Vol. 1. Walter de Gruyter, New York,1991, pp. 163–166.Google Scholar
- 37.Jones, G. In Holick, M.F., (Ed.), Vitamin D: Physiology, Molecular Biology, and Clinical Applications, Vol. 1. Humana Press Inc., Totowa, NJ,1999, pp. 57–84.Google Scholar